Treatment landscape of triple-negative breast cancer - expanded options, evolving needs

被引：813

作者：

Bianchini, Giampaolo ^{[1
,2
]}

De Angelis, Carmine ^{[3
,4
]}

Licata, Luca ^{[1
]}

Gianni, Luca ^{[5
]}

机构：

[1] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] Univ Federico II, Dept Clin Med & Surg, Naples, Italy

[4] Baylor Coll Med, Laster & Sue Smith Breast Ctr, Houston, TX 77030 USA

[5] Gianni Bonadonna Fdn, Milan, Italy

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2022年 / 19卷 / 02期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; PHASE-III TRIAL; PEMBROLIZUMAB PLUS CHEMOTHERAPY; CELL-INTRINSIC MECHANISMS; DOUBLE-BLIND; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; SACITUZUMAB GOVITECAN; ADJUVANT CAPECITABINE; NAB-PACLITAXEL;

D O I：

10.1038/s41571-021-00565-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least favourable outcomes. In the past few years, advances in omics technologies have shed light on the relevance of the TNBC microenvironment heterogeneity, unveiling a close dynamic relationship with cancer cell features. An improved understanding of tumour-immune system co-evolution supports the need to adopt a more comprehensive view of TNBC as an ecosystem that encompasses the intrinsic and extrinsic features of cancer cells. This new appreciation of the biology of TNBC has already led to the development of novel targeted agents, including PARP inhibitors, antibody-drug conjugates and immune-checkpoint inhibitors, which are revolutionizing the therapeutic landscape and providing new opportunities both for patients with early-stage TNBC and for those with advanced-stage disease. The current therapeutic scenario is only the tip of the iceberg, as hundreds of new compounds and combinations are in development. The translation of these experimental therapies into clinical benefit is a welcome and ongoing challenge. In this Review, we describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can define different levels of risk and provide improved opportunities for tailoring treatment. In the past few years, advances in omics technologies have led to a better understanding of the heterogeneity of triple-negative breast cancers (TNBCs) and their microenvironment, supporting a view of this breast cancer subtype as an ecosystem that encompasses the intrinsic and extrinsic features of cancer cells. The authors of this Review describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can provide improved opportunities for tailoring treatment.

引用

页码：91 / 113

页数：23

共 217 条

[1] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study [J].

Adams, S. ;

Loi, S. ;

Toppmeyer, D. ;

Cescon, D. W. ;

De Laurentiis, M. ;

Nanda, R. ;

Winer, E. P. ;

Mukai, H. ;

Tamura, K. ;

Armstrong, A. ;

Liu, M. C. ;

Iwata, H. ;

Ryvo, L. ;

Wimberger, P. ;

Rugo, H. S. ;

Tan, A. R. ;

Jia, L. ;

Ding, Y. ;

Karantza, V. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :405-411

[2] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[3] Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer [J].

Ali, H. Raza ;

Jackson, Hartland W. ;

Zanotelli, Vito R. T. ;

Danenberg, Esther ;

Fischer, Jana R. ;

Bardwell, Helen ;

Provenzano, Elena ;

Rueda, Oscar M. ;

Chin, Suet-Feung ;

Aparicio, Samuel ;

Caldas, Carlos ;

Bodenmiller, Bernd .

NATURE CANCER, 2020, 1 (02) :163-+

[4] Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. [J].

Alva, Ajjai Shivaram ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Alvarez, Ricardo H. ;

Calfa, Carmen Julia ;

Khalil, Maged F. ;

Ahn, Eugene R. ;

Cannon, Timothy Lewis ;

Crilley, Pamela A. ;

Fisher, Julie Gottlieb ;

Haslem, Derrick S. ;

Shrestha, Sagun ;

Antonelli, Kaitlyn R. ;

Butler, Nicole L. ;

Warren, Sasha L. ;

Rygiel, Andrew Lawrence ;

Ranasinghe, Shamika ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[5] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[6] Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer [J].

Asghar, Uzma S. ;

Barr, Alexis R. ;

Cutts, Ros ;

Beaney, Matthew ;

Babina, Irina ;

Sampath, Deepak ;

Giltnane, Jennifer ;

Lacap, Jennifer Arca ;

Crocker, Lisa ;

Young, Amy ;

Pearson, Alex ;

Herrera-Abreu, Maria Teresa ;

Bakal, Chris ;

Turner, Nicholas C. .

CLINICAL CANCER RESEARCH, 2017, 23 (18) :5561-5572

[7] Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment [J].

Azizi, Elham ;

Carr, Ambrose J. ;

Plitas, George ;

Cornish, Andrew E. ;

Konopacki, Catherine ;

Prabhakaran, Sandhya ;

Nainys, Juozas ;

Wu, Kenmin ;

Kiseliovas, Vaidotas ;

Setty, Manu ;

Choi, Kristy ;

Fromme, Rachel M. ;

Phuong Dao ;

McKenney, Peter T. ;

Wasti, Ruby C. ;

Kadaveru, Krishna ;

Mazutis, Linas ;

Rudensky, Alexander Y. ;

Pe'er, Dana .

CELL, 2018, 174 (05) :1293-+

[8] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial [J].

Bachelot, Thomas ;

Filleron, Thomas ;

Bieche, Ivan ;

Arnedos, Monica ;

Campone, Mario ;

Dalenc, Florence ;

Coussy, Florence ;

Sablin, Marie-Paule ;

Debled, Marc ;

Lefeuvre-Plesse, Claudia ;

Goncalves, Anthony ;

Reynier, Marie-Ange Mouret ;

Jacot, William ;

You, Benoit ;

Barthelemy, Philippe ;

Verret, Benjamin ;

Isambert, Nicolas ;

Tchiknavorian, Xavier ;

Levy, Christelle ;

Thery, Jean-Christophe ;

L'Haridon, Tifenn ;

Ferrero, Jean-Marc ;

Mege, Alice ;

Del Piano, Francesco ;

Rouleau, Etienne ;

Tran-Dien, Alicia ;

Adam, Julien ;

Lusque, Amelie ;

Jimenez, Marta ;

Jacquet, Alexandra ;

Garberis, Ingrid ;

Andre, Fabrice .

NATURE MEDICINE, 2021, 27 (02) :250-+

[9] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J].

Bardia, A. ;

Tolaney, S. M. ;

Punie, K. ;

Loirat, D. ;

Oliveira, M. ;

Kalinsky, K. ;

Zelnak, A. ;

Aftimos, P. ;

Dalenc, F. ;

Sardesai, S. ;

Hamilton, E. ;

Sharma, P. ;

Recalde, S. ;

Gil, E. C. ;

Traina, T. ;

O'Shaughnessy, J. ;

Cortes, J. ;

Tsai, M. ;

Vahdat, L. ;

Dieras, V ;

Carey, L. A. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. ;

Itri, L. M. ;

Hurvitz, S. A. .

ANNALS OF ONCOLOGY, 2021, 32 (09) :1148-1156

[10] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

← 1 2 3 4 5 6 7 8 9 10 →